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ABSTRACT
Background: The foremost problems of nasopharyngeal carcinoma (NPC) management are high loco-regional remission, local
recurrence and spreading rate post therapy. Photodynamic therapy (PDT) has been done for treatment of tumors less than 1 cm in
size and depth in a very difficult location, where radical excision by surgery was not possible. The aim of this study is determining
5-year-overall survival rate of local-partial remission of NPC after standard therapy followed by additional PDT.
Method: The survival study is subjected to the 5 years-overall survival rate of local-partial remission. Photosensitizer (FoscanR)
0,15mg/kgBW was injected to NPC patients and followed by 20 joule/cm2, 642 wave length and 100 watts/cm2 irradiants non
thermal laser illumination 96 hours after injection. The PDT result was confirmed with biopsy, CT scan, upper abdominal USG,
thoracic radiograph and bone survey for 12 weeks after treatment. Follow up was done every 3 months in first year, continued every
6 months in the second year, and followed once a year. The sample collected from January 2005 to December 2010, and 33 cases
met the inclusion and exclusion criterias, but only 20 cases were eligible inclusion criteria. The 5 years-overall survival was defined
as the time from diagnosis to death from any cause or last follow up, calculated by Kaplan Meier survival analysis.
Results: The 5-year-overall survival rate was 50%.
Conclusion: PDT as an additional treatment for small local-partial remission in NPC post treatment is an alternative therapy to
improve the treatment outcome and survival rate.
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ABSTRAK
Photodynamic therapy sebagai terapi ajuvan karsinoma nasofaring remisi lokal-parsial setelah terapi standar di RSUP Dr. Sardjito
Yogyakarta: Studi analisis angka kehidupan lima tahun
Latar belakang: Problem utama terapi standar karsinoma nasofaring (KNF) adalah rendahnya angka keberhasilan terapi, terutama
adanya remisi parsial, baik pada tumor primer maupun metastasis. Photodynamic therapy (PDT) telah digunakan untuk pengobatan
tumor di superfisial, dengan diameter kurang dari 1 cm, terutama pada  tumor yang letaknya tersembunyi dan sulit dioperasi secara
radikal. Penelitian ini bertujuan menentukan angka kehidupan 5 tahun pada penderita KNF dengan remisi parsial pada tumor
primernya, setelah diterapi secara standar dan dilakukan PDT sebagai terapi tambahan.
Metode: Studi analisis kesintasan terhadap kehidupan 5 tahun penderita KNF yang mengalami remisi lokal-parsial setelah terapi
standar dan PDT. Photosensitizer (FoscanR) 0,15mg/kgBW diinjeksikan pada penderita KNF, dan setelah 96 jam, dilanjutkan
dengan irradiants non thermal laser illumination sebesar 20 joule/cm2, panjang gelombang 642 dan 100 watts/cm2. Hasil PDT
dikonfirmasi dengan biopsi, CT scan, USG abdomen, rontgen thoraks dan bone survey pada 12 minggu setelah terapi. Tahun
pertama, dilakukan follow up setiap 3 bulan, di tahun kedua setiap 6 bulan, dan selanjutnya setiap setahun sekali. Sampel didapat
dari Januari 2005 sampai Desember 2010, dimana 33 pasien KNF post PDT memenuhi kriteria inklusi dan eksklusi, namun hanya
20 pasien yang memenuhi kriteria inklusi 5-tahun-follow up. Angka kehidupan 5 tahun ditentukan berdasarkan saat diagnosis
sampai kematian penderita, atau sampai folllow up terakhir, dihitung dengan analisis kesintasan Kaplan Meier.
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Hasil: Angka kehidupan keseluruhan selama 5 tahun adalah
50%.
Simpulan: PDT sebagai tambahan terapi terhadap KNF yang
mengalami remisi parsial paska terapi standar dapat
digunakan sebagai terapi alternatif terhadap KNF yang
mengalami remisi parsial paska terapi standar.
INTRODUCTION
Nasopharyngeal carcinoma is the most frequent
malignancy among head and neck malignancies,
especially in male population. It has different clinical
characteristics from other head and neck malignancies
in which it is very invasive and may undergo rapid
metastasis.1,2
The epidemiology of NPC is quite unique and distinct
from other malignant tumors arising from head and
neck.  In Europe and USA, NPC is an uncommon type
of tumor. However, NPC is more common among
Southeast Asia countries, Southern Chinese and some of
African population. The highest incidence of NPC can
be found in province of Guangdong, Southern China
with 40-50 new cases per 100.000 population per year.
The early stage of NPC symptoms are unspecific,
causing NPC patients to present advance stage, which
therefore result in unsatisfactory therapy outcome.1,3
Currently the main modality of early NPC therapy is
radiotherapy. The foremost problems are, loco-regional
partial remission, local recurrent rate, and spread after
radiotherapy remain high, which was around 18%-
45%.4,5 In advanced stage, NPC is treated with a
combination of radiotherapy and chemotherapy.
Chemotherapy can be given before radiotherapy (neo-
adjuvant chemotherapy), or after radiotherapy (adjuvant
chemotherapy), or simultaneously (concurrent chemo-
therapy). The aims of additional chemotherapy are to
decrease the loco-regional recurrence and distant
metastasis, as well as to increase disease free or overall
survival. The main problem in NPC partial result after
full dose treatment is the additional treatment. Re
irradiation/chemotherapy need waiting time to over-
come the damage of normal tissues and side effects of
radio and chemotherapy.6 Up until now the treatment
option for recurrent and persisten NPC are limited.
The study of Lee, et al. reported that early stage NPC
patients who underwent radiotherapy, had completed
remission by 80-90%, and the 5-year-overall survival
rate was higher. However, for the late stage patients, it
dramatically dropped to 10-40%. If distant metastasis
was present, 85% of NPC patients would die in the first
year.7
The therapeutic success rate for NPC in each domestic
and International Centre or Hospital are variated.1,6,8
The presence of distant metastasis before therapy,
partial-local (uncomplete) remission and recurrences
after therapy is an important factor for the therapy
success rate.
Photodynamic therapy (PDT) is a method of local
cancer treatment based on administration of
photosensitizing substance selectively absorbed by
tumor cells which lead after exposure to optical
radiation, to tumor destruction.9 Photodynamic therapy
is clinically approved, minimal invasive therapeutic
procedure that can exert a selective cytotoxic activity
toward malignant cells.10
The use of PDT in NPC treatment is relatively new, and
has been used for superficial, less than 1 cm in depth
and less than 3 cm in size in both benign and malignant
tumors since 1980, i.e. those with very difficult
locations where surgery approach for radical excision
was not possible. The mechanism of PDT is an
interaction among laser, molecular oxygen and
sensitizer agent. Photo sensitizer causes laser energy to
be absorbed by tumor tissue, which eventualy makes the
tumor tissue damaged and undergo necrosis. PDT can
be done more than one time in the short periode, and not
necessary to wait in long time.11,12
Photo sensitizer injected into the body will become
active when it is interacting with molecular oxygen, and
thus produce singlet oxygen, which is followed by
bio molecular reaction, as well as performing cytotoxic
products that causes cell and tissue damages. Photo
sensitizer also reacts directly with cell and produces free
radicals.10,12
Additional action of PDT in tumor therapy is making
thrombus in tumor vascularization through
thromboxane production, which may result in hypoxia
or anoxia, thus leading to cell death. Photodynamic
therapy can also strengthen apoptosis process by
induceing cytochrome-C production from mitochondria
to cytoplasm.10
The objective of the study is to determine 5 year-overall
survival rate of local-partial remission of NPC patients
post standard therapy who received additional PDT.
METHOD
This was an survival analysis study with retrospective
design. Five-year-overall survival was defined as the
time from diagnosis to death from any cause or lost of
follow up. The zero point was the time of NPC
diagnosed, the end point of the study was death in
5 years during follow up, which was calculated by the
Kaplan Meier survival method. The standard NPC
therapy in Sardjito Hospital is radiotherapy 6600-7000
Cgy forearly stage. Neo adjuvant chemotherapy (Cis
platinum combined with 5 flurouracyl) is administered
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for advanced stage. Sample collection started from
January 2011, retrospectively.
In Sardjito Hospital Yogyakarta, phase II PDT study has
been done since 2005. The inclusion criteria were local-
partial remission, tumor volume not more than 1 cm3,
absence of regional and distant metastasis confirmed
with biopsy, CT Scan, upper abdominal USG, liver
function test, Ro thorax, and bone survey. The PDT
candidate patients who agreed to take part in the study
had to sign informed consent. Photo sensitizer (FoscanR)
0,15mg/kgBW was injected to NPC patients and
followed by 20 joule/cm2, 642 wave length and 100
watts/cm2 irradiants non thermal laser illumination 96
hours after injection. The PDT result was confirmed
with biopsy, CT scan, upper abdominal USG, thoracic
photograph, and bone survey 12 weeks after the
treatment was given. Follow up was done every 3
months in the first year, and was continued every
6 months in the second year, and was followed once a
year. The ethical clearance was approved by
Gadjahmada ethical commision, and all statistical
analyses were done with SPSS version 17.0.
RESULTS
The sample of study were collected from January 2005
to December 2010. Thirty three NPC patients post PDT,
but only 20 NPC patients were met the inclusion and
exclusion criteria, 13 patients were excluded due to
primary tumor more than 1 cm3 in size, consisting of 10
males and 10 females with an age range of 22-73 years
old, the mean age was 46 year-old, and follow up range
was 17-86 months. The sample characteristics were
shown in Table 1.
Table 1. Sample characteristics
PDT %
Age
10 - 19 yrs - -
20 - 29 yrs 3 15%
30 - 39 yrs 2 10%
40 - 49 yrs 3 15%
50 - 59 yrs 9 45%
60 - 69 yrs 2 10%
70 - 79 yrs 1 5%
Stage
III 12 60%
IVA 3 15%
IVB 5 25%
Gender
Male 10 50%
Female 10 50%
Histopathology
WHO II 5 25%
WHO III 15 75%
The 5-year-overall survival rate of local-partial
remission of NPC with additional PDT post standard
therapy was 50% (Figure 1). There was no significant
difference betwen 5-year-over all survival rate of the
sample of >46 year-old and ≤46 year-old with p=0.457
and Log rank 0.554 (Figure 2).
Figure 1. Five-years overall survival rate
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Figure 2. The difference of 5 year-overall survival rate between >46 & ≤46 years old
DISCUSSION
Many researchers reported that the therapeutic success
rate of NPC in each domestic and international centre or
hospitals varied.1,6,8 This conditions due to the
equipment for established NPC diagnose and treatment
scheme are not same. The magnetic resonance imaging
(MRI) examination for NPC staging is one of the
significant prognostic factors beside radiotherapy
schedule and chemotherapy scheme.13 Unfortunenatelly
not all of hospitals in Indonesia has not been completed
yet with MRI instrument, and the radiotherapy is not on
scheduled (too long waiting time) due to the limited
radiotherapy equipment. The 3-years-overall survival
rate in head and neck malignancy treated with
chemotherapy plus radiotherapy was significantly
different from that in head and neck malignancy treated
with surgery plus radiotherapy (p=0.02).14
Many overall survival rates of NPC studies have been
published. According to Ma, et al. study in 5 years
survival rate between NPC completed with MRI
examination, treated with on time scheduled radio-
therapy combined with chemotherapy and NPC treated
with radiotherapy only, described that there were no
significant differences between the 5-year-overall
survival rate in NPC treated with radiotherapy
combined with chemotherapy, and NPC treated radio-
therapy only. The  rate was 63% and 56% (p>0.05).2 A
retrospective study by Khademi, et al. confirmed  that
2-years-overall survival rate of all stages of NPC post
therapy was only 35%. The incidence of local relapse
and distant metastasis in the advanced disease is
remarkable and the patients with T2-4N2-3 had worse
prognosis than those with T1-2N0. It can be assumed that
the different therapeutic success rates might be due to
the different diagnostic and therapy scheme or dose and
radio-diagnostic and/or radio-therapy equipment in
every centre or hospitals. Consequently, different
strategies may be needed to improve  the treatment out
come.6
The research of Wideman, et al. reported that 6 NPC
patients with T1-2 post chemo radiation without
lymphnode and distance metastasis had complete
respons after PDT, and 1 patient died 12 months after
PDT cause of unrelated cause.15
Hariwiyanto (2010) in earlier research showing that in
Sardjito Hospital, the 5-years-overall survival rate in
total remission of 28 patients NPC post therapy was
42% and significantly dropped to 20% in partial loco-
regional remission of NPC post therapy without
additional therapy (p<0.05).16 The result of this study in
accordance to our earlier research, showing that the 5
years survival rate of NPC partial remission plus PDT
as additional therapy was 50%, significantly better than
NPC partial remission without additional treatment
(20%).16
Another result of the study was no difference of
5-years-overall survival rate between age >46 year-old
and ≤46 year-old (p=0.457; log rank=0.554). The result
was consistent with that of Liu, et al. study, reporting
there was no diffference in 5-year-overall survival rate
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between NPC patients <50 year-old and those ≥50 year-
old (p=0.069).1 Our previous study also discovered that
there was no significant different therapy response
between NPC >40 and year-old and NPC ≤40 year-old
(p>0.05).17 The NPC tumor stage was not analysed in
this research due to the sample size was not homogen
and limited between each stage.
CONCLUSION
Since the frequent of partial remision is still high and
treatment option for recurrent and persistent NPC are
limited, the survival rate poor and the complications is
severe, alternative treatment modalities is needed with
more efficacy and less morbidity. Photodynamic
therapy as an additional treatment for small local-partial
remission (tumor less than  1 cm) in NPC post treatment
is promising as an alternative therapy strategy to
improve the treatment outcome and survival rate.
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